Form 4: Crinetics Pharmaceuticals Executive Reports Stock Transactio
Insider Transaction (Form 4)
Isabel Kalofonos, Chief Commercial Officer of Crinetics Pharmaceuticals, Inc., reported multiple transactions in common stock on September 1, 2026.
Summary
- Disposition to the issuer: disposed of 1,669 Common Stock at $85.00 ($141,865) on September 1, 2026; holds 34,000 after (Direct).
- Disposition to the issuer: disposed of 34,000 Common Stock at $85.00 ($2,890,000) on September 1, 2026 (Direct).
- Disposition to the issuer: disposed of 97,500 Stock Option (Right to Buy) at $44.41 ($4,329,975) on September 1, 2026 (Direct).
- Disposition to the issuer: disposed of 55,000 Stock Option (Right to Buy) at $41.21 ($2,266,550) on September 1, 2026 (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Isabel Kalofonos — Officer (Chief Commercial Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-01 | Disposition to the issuer | Common Stock | 1,669 | $85 | $141.9K | 34,000 |
| 2026-09-01 | Disposition to the issuer | Common Stock | 34,000 | $85 | $2.9M | 0 |
| 2026-09-01 | Disposition to the issuer | Stock Option (Right to Buy) | 97,500 | $44 | $4.3M | 0 |
| 2026-09-01 | Disposition to the issuer | Stock Option (Right to Buy) | 55,000 | $41 | $2.3M | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-01 | Disposition to the issuer (1,669 shares) |
| 2026-09-01 | Disposition to the issuer (34,000 shares) |
| 2026-09-01 | Disposition to the issuer (97,500 shares) |
| 2026-09-01 | Disposition to the issuer (55,000 shares) |
Keywords
insider transaction, Form 4, CRNX, Crinetics Pharmaceuticals, Inc., neutral, Isabel Kalofonos
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.